Compare UE & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UE | IMNM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | UE | IMNM |
|---|---|---|
| Price | $20.76 | $23.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $22.00 | ★ $32.10 |
| AVG Volume (30 Days) | 964.6K | ★ 1.7M |
| Earning Date | 02-11-2026 | 03-18-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 23.73 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $471,935,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.53 |
| P/E Ratio | $27.96 | ★ N/A |
| Revenue Growth | ★ 6.06 | N/A |
| 52 Week Low | $15.66 | $5.15 |
| 52 Week High | $21.87 | $27.65 |
| Indicator | UE | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 48.17 |
| Support Level | $20.71 | $24.03 |
| Resistance Level | $21.30 | $27.65 |
| Average True Range (ATR) | 0.52 | 1.54 |
| MACD | 0.18 | -0.32 |
| Stochastic Oscillator | 65.35 | 13.27 |
Urban Edge Properties is a real estate investment trust principally focused on the management and development of retail real estate properties in urban communities in the U.S. Having originally been created to hold the majority of Vornado Realty Trust's shopping center businesses, Urban Edge's asset portfolio is mostly composed of shopping centers and malls in terms of total square footage. The company's holdings include necessity and convenience-oriented retailers, such as department stores, grocers, health clubs, and restaurants. Urban Edge's properties are mainly located in the New York City metropolitan region and within the DC to Boston corridor. The company generates nearly all of its revenue through the collection of rent from a large number of tenants.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.